Skip to content

Tango Therapeutics TNGX Income Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$6.19M-15.2%$5.63M-28.6%$5.76M-30.7%$6.48M-22.7%$7.31M-5.8%
$56.99M+39.0%$62.38M+48.3%$66.5M+53.3%$24.3M-42.8%$40.99M+10.1%
$129.26M-9.2%$132.17M-8.2%$134M-5.2%$136.45M+0.9%$142.3M+13.6%
$174.52M-6.6%$173.67M-7.5%$176.84M-3.4%$181.58M+3.8%$186.86M+14.4%
$174.52M-6.6%$173.67M-7.5%$176.84M-3.4%$181.58M+3.8%$186.86M+14.4%
$10.27M-25.6%$9.7M-37.4%$9.93M-39.9%$11.89M-26.3%$13.81M-5.8%
-$107.23M+18.9%-$101.59M+22.0%-$100.52M+18.5%-$145.57M-25.0%-$132.26M-18.5%
-188.2%+135pp-162.9%+147pp-151.1%+133pp-599.1%-325pp-322.7%-22.8pp
-$0.83+31.4%-$0.87+27.5%-$0.91+21.6%-$1.32-17.9%-$1.21-9.0%
481.2M+10.3%448M+3.2%441M+5.1%438.6M+7.5%436.3M+12.4%
-$107.54M+18.4%-$101.71M+21.9%-$101.14M+17.1%-$145.14M-25.9%-$131.81M-20.2%
$6.19M-15.2%$5.63M-28.6%$5.76M-30.7%$6.48M-22.7%$7.31M-5.8%
$302.34M+6,355%$222.5M+367%$4.09M-91.5%$3.95M-96.9%$4.68M-96.3%
-$61.83M-148%-$40.87M-147%$146.91M+116%$132.01M$127.93M
-$141.55M-4.6%-$138.89M-5.6%-$145.82M-19.2%-$148.25M-23.5%-$135.34M-11.9%
$4.07M-37.3%$4.07M-46.5%$4.17M-49.2%$5.42M-30.2%$6.5M-5.9%
$564K$36K
-$115.41M+19.5%-$109.01M+23.8%-$107.91M+21.3%-$154.8M-19.1%-$143.37M-15.9%
-202.5%+147pp-174.7%+165pp-162.3%+154pp-637.1%-331pp-349.8%-17.6pp
-$117.53M+19.4%-$111.29M+23.6%-$110.34M+21.0%-$157.29M-18.8%-$145.87M-15.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Tango Therapeutics's income statement data come from?
Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.